Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Shonali Midha

12PUBLICATIONS

92CO-AUTHORS

Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markersGene and molecular therapy

Featured researcher

Get your video featured.

Publish with JoVE

Featured researcher

Get your video featured.

Publish with JoVE

Publications (12)

Sort by Publication Date:

|Mar 28, 2026

Real-world outcomes with elranatamab in multiple myeloma: a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy Consortium.

Andrew J Portuguese, James A Davis, Shahzad Raza

|Mar 21, 2026

Efficacy of stem cell boost (SCB) for chimeric antigen receptor-T cell therapy (CAR-T)-related hematologic toxicity in patients with relapsed/refractory multiple myeloma (RRMM)-real world experience from the US multiple myeloma immunotherapy consortium.

Cindy Varga, Myra Robinson, James A Davis

|Oct 30, 2025

Mezigdomide for multiple myeloma: a focus on phase 2 trial data.

Clifton C Mo, Yuxin Liu, Omar Nadeem

|Oct 11, 2025

Predictors of Delayed Responses to Teclistamab in Multiple Myeloma After Initial Non-Response.

Rahul Banerjee, Gurbakhash Kaur, Beatrice M Razzo

|Aug 08, 2025

Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium.

Beatrice M Razzo, Shonali Midha, Andrew J Portuguese

|Jul 09, 2025

Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium.

Beatrice M Razzo, Shonali Midha, Andrew J Portuguese

Pageof 2

Frequent Collaborators

6 joint publications

Aimaz Afrough

6 joint publications

Doris K Hansen

6 joint publications

Adam S Sperling

6 joint publications

Surbhi Sidana

6 joint publications

Megan M Herr

5 joint publications

Yi Lin

5 joint publications

Omar Castaneda Puglianini

5 joint publications

James A Davis

5 joint publications

Douglas W Sborov

5 joint publications

Jack Khouri

Frequent Collaborators

6 joint publications

Aimaz Afrough

6 joint publications

Doris K Hansen

6 joint publications

Adam S Sperling

6 joint publications

Surbhi Sidana

Top Related Videos

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on : Feb 10, 2023

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on : May 15, 2019

See more related videos

Top Related Videos

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on : Feb 10, 2023

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on : May 15, 2019

See more related videos